This Cannabinoids-Focused Pharma Co. Sees 50% YoY Surge In Revenue In 2023, Trims Losses
This Cannabinoids-Focused Pharma Co. Sees 50% YoY Surge In Revenue In 2023, Trims Losses
这家专注于大麻素的制药公司预计2023年收入将同比增长50％，减少亏损
MediPharm Labs Corp. (TSX:LABS) (OTCQB:MEDIF) (FSE: MLZ) announced its financial results on Wednesday for the full year and three months ended Dec. 31, 2023.
MediPharm Labs Corp.（多伦多证券交易所股票代码：LABS）（OTCQB: MEDIF）（FSE: MLZ）周三公布了截至2023年12月31日的全年和三个月的财务业绩。
Net revenue grew to CA$33 million ($24.3 million) in 2023, from CA$22.1 million in 2022, representing roughly a 50% year-over-year increase, the company said in a press release.
该公司在一份新闻稿中表示，净收入从2022年的2210万加元增长到2023年的3300万加元（合2430万美元），同比增长约50％。
"Over the years we have invested in our infrastructure as a high quality and high-capacity pharmaceutical grade manufacturer, allowing us to grow sales with new opportunities and markets, without additional investment into capital or resources," CEO David Pidduck said. "We are proud of the work completed in 2023 and excited...
首席执行官戴维·皮德杜克说：“多年来，我们作为高质量、高产能的医药级制造商投资了基础设施，这使我们能...
登录免费看全文
登录/注册